Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG006 in advanced small cell lung cancer or neuroendocrine carcinoma
CTR20240667Phase 2Active
- Sponsor
- Zelgen
- Start
- Sep 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alveltamig in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), large cell neuroendocrine carcinoma (LCNEC), sponsored by Zelgen. Started Sep 2024; status: active.
02
Drugs
alveltamig
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on CTR20240667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240667.